Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population - Université de Rennes Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022

Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population

Résumé

Autologous stem cell transplantation (ASCT) and chimeric antigen receptor (CAR) T-cells are two therapeutic options for relapsed/refractory diffuse large B-cell lymphoma. Both are intensive and potentially curative therapies but differ in their efficacy and toxicity. ASCT may be offered to 'fit' patients (i.e. usually young with limited comorbidities) with chemosensitive disease. On the other hand, real world studies have shown that CAR T-cells may be safely administered to less fit and older patients. Thus, there is a potentially significant population of patients who may be offered CAR T-cell therapy despite not being eligible for ASCT. As the relative role of ASCT and CAR T-cells evolves, recognising and defining this population may be increasingly relevant. Here, we review criteria which may help identify this 'ASCT-ineligible but CAR T-cells eligible' population of patients.

Domaines

Cancer

Dates et versions

hal-04098893 , version 1 (16-05-2023)

Identifiants

Citer

Samuel Vic, Jean Lemoine, Philippe Armand, François Lemonnier, Roch Houot. Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population. European Journal of Cancer, 2022, 175, pp.246-253. ⟨10.1016/j.ejca.2022.08.019⟩. ⟨hal-04098893⟩
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More